首页> 外文期刊>Arthroscopy: the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association >Improved outcomes with combined autologous chondrocyte implantation and patellofemoral osteotomy versus isolated autologous chondrocyte implantation
【24h】

Improved outcomes with combined autologous chondrocyte implantation and patellofemoral osteotomy versus isolated autologous chondrocyte implantation

机译:联合自体软骨细胞植入和pa股截骨术相比单独的自体软骨细胞植入可改善预后

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: To compare clinical outcomes of patients undergoing isolated patellofemoral autologous chondrocyte implantation (ACI) and ACI combined with patellofemoral realignment. Methods: A systematic review was performed by use of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines/checklist. We searched PubMed, CINAHL (Cumulative Index to Nursing and Allied Health Literature), SportDiscus, and the Cochrane Central Register of Controlled Trials databases from 1946 through February 2012 to determine whether a difference exists in outcomes of combined ACI and osteotomy versus isolated ACI (minimum 2 years' follow-up). Studies were included only if outcomes were reported separately for both isolated ACI and combined ACI and osteotomy. All ACI generations were eligible for inclusion. Patellofemoral osteotomies eligible for inclusion were anteriorization, medialization, or anteromedialization. All patient-, limb-, and defect-specific characteristics were assessed. All reported clinical scores, radiographic and histologic outcomes, and complications/reoperations were analyzed. Risk of bias was assessed within all studies. Results: Eleven studies (10 Level III or IV evidence) (366 subjects) were included. Of the defects treated, 78% were located on the patella and 22% on the trochlea. The mean subject age was 33.3 years. Twenty-three percent of subjects underwent concomitant osteotomy. The mean length of follow-up was 4.2 years. Significant (P <.05) improvements in patients undergoing both isolated ACI and combined ACI and osteotomy for patellofemoral chondral defects were observed in all studies. Three studies directly compared isolated ACI and combined ACI and osteotomy, with significantly (P <.05) greater improvements shown in patients undergoing combined osteotomy and ACI (International Knee Documentation Committee subjective score, Lysholm score, Knee Injury and Osteoarthritis Outcome Score, Tegner score, modified Cincinnati score, Short Form 12 score, and Short Form 36 score). There was no significant difference between groups in the rate of postoperative complications overall. Conclusions: This review showed statistically significant improvements in patients undergoing both isolated ACI and ACI combined with osteotomy for patellofemoral chondral defects in all studies. When individual studies compared these 2 groups (3 studies), significantly greater improvements in multiple clinical outcomes in subjects undergoing ACI combined with osteotomy were observed. There was no significant difference in the rate of total complications between groups. Level of Evidence: Level IV, systematic review of studies with minimum Level IV evidence, retrospective case series.
机译:目的:比较接受孤立isolated股自体软骨细胞植入(ACI)和ACI联合pa股复位的患者的临床结局。方法:通过使用PRISMA(系统评价和荟萃分析的首选报告项目)指南/清单进行系统的评价。我们搜索了1946年至2012年2月间的PubMed,CINAHL(护理和相关健康文献的累积索引),SportDiscus和对照试验的Cochrane中央登记册,以确定ACI和截骨术与单独ACI联合治疗的结果是否存在差异(最低2年的随访)。仅当单独报告单独的ACI以及联合ACI和截骨术的结局分别报告时,才纳入研究。所有ACI代都有资格被纳入。符合纳入条件的股截骨术是前路化,中度化或前中度化。评估了所有患者,肢体和缺陷特有的特征。分析所有报告的临床评分,影像学和组织学结果以及并发症/再次手术。所有研究均评估了偏倚风险。结果:纳入了11项研究(10项III或IV级证据)(366名受试者)。在治疗的缺损中,有78%位于骨上,而22%位于滑车上。平均受试者年龄为33.3岁。 23%的受试者同时进行了截骨术。平均随访时间为4.2年。在所有研究中均观察到接受孤立ACI和联合ACI联合截骨术治疗pa股软骨缺损的患者的显着(P <.05)改善。三项研究直接比较了单独的ACI和联合的ACI与截骨术,在联合截骨和ACI的患者中显示了显着(P <.05)改善(国际膝关节文献委员会主观评分,Lysholm评分,膝关节损伤和骨关节炎结果评分,Tegner评分,修改后的辛辛那提(Cincinnati)得分,简短表格12得分和简短表格36得分)。两组之间的总体术后并发症发生率没有显着差异。结论:本评价显示,在所有研究中,接受孤立ACI和ACI联合截骨术治疗pa股软骨缺损的患者均具有统计学上的显着改善。当单独的研究比较这两组(3个研究)时,在接受ACI联合截骨术的受试者中,在多个临床结局方面观察到了更大的改善。两组之间的总并发症发生率没有显着差异。证据级别:第四级,用最少的第四级证据对研究进行系统的回顾,回顾性病例系列。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号